Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) has approved ROMVIMZA™ (vimseltinib), a kinase ...

Blueprint Medicines' fourth-quarter earnings and sales miss estimates. Shares of the company decline following the ...

The prognosis of patients with gastrointestinal stromal tumors is significantly impacted by gastrointestinal bleeding.

The focus of the presentation will be on the subgroup of patients who have received 100mg bezuclastinib for at least 48 weeks to highlight the symptomatic benefits of long-term use.

Patients with non-metastatic GIST treated with neoadjuvant TKIs prior to surgery experienced a benefit which led to less ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Scientists of the University Medical Center Göttingen (UMG) have identified new interactions between pancreatic cancer cells ...

Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...

Rare cancers are less known and pose challenges due to limited research and diagnostic difficulties. Environmental factors, ...

Marwan G. Fakih, MD, explains the implications of the findings from the phase 2 trial of balstilimab plus botensilimab for the treatment of patients with microsatellite stable metastatic colorectal ...

Immunohistochemistry (IHC) performed showed tumor cells positive for cytokeratin 20 (CK20) and MUC5AC. The tumor cells were negative for cytokeratin 7 (CK7), chromogranin, and synaptophysin. Upper ...